Open original FDA record ↗Recall record
- FDA identifier
- Z-2521-2025
- Company in FDA record
- CARIS LIFE SCIENCES
- FDA classification date
- Sep 4, 2025
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Due to an incorrect test results provided that indicated the incorrect drug therapy recommendation
Source facts
- Action
- On 07/14/2025, the firm emailed an "URGENT: MEDICAL DEVICE RECALL" Letter its customer that inform them that an incorrect CDx report was issued on April 14, 2025 with the wild-type KRAS/NRAS results with VECTIBIX (panitumumab) listed as a therapeutic option. The potential cause of the issue occurred due to two unanticipated events occurring in succession within the operational aspect of the report generation software processes of MI Cancer Seek. These two events in succession resulted in a failing file. Customer was provided with an amended report and instructed to: -Review the report paying careful attention to the amended CDx report with the header "MI Cancer Seek" which changes the wild-type KRAS/NRAS result Detected to wild-type KRAS/NRAS result to Not Detected and the KRAS G12C variant listed in the Other Alterations and Biomarkers Identified section towards the bottom of the page. The new CDx report also includes the banner, Findings did not yield any biomarker results with Companion Diagnostic (CDx) claims . For questions, contact Regulatory Affairs at 351-220-3883 Monday thru Friday 8:00 AM to 5:00 PM Mountain Standard Time or email Pcarter@carisls.com. In addition Caris Customer Support +1-888-979-8669
- Initiated
- 2025-06-17
- Root cause
- Software design
- Distribution
- U.S. Nationwide distribution in the state of NY.
- Recall number
- Z-2521-2025
- Recall status
- Open, Classified
- CDRH record ID
- 214979
- FDA classified
- 2025-09-04
- Recall event number
- 97258